SeaStar Medical to Showcase Initial SAVE Registry Findings on QUELIMMUNE for Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children | Intellectia.AI
SeaStar Medical to Showcase Initial SAVE Registry Findings on QUELIMMUNE for Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children
Written by Emily J. Thompson, Senior Investment Analyst
Presentation of SAVE Registry Results: SeaStar Medical will present preliminary results from the SAVE Surveillance Registry at the 5th International Symposium on Acute Kidney Injury in Children, focusing on the QUELIMMUNE therapy's role in treating critically ill pediatric patients with Acute Kidney Injury (AKI) and sepsis.
QUELIMMUNE Therapy Overview: The QUELIMMUNE therapy, approved for pediatric patients with AKI and sepsis, has shown a 77% survival rate compared to standard care, with significant improvements in kidney function among survivors, highlighting its potential impact on treatment outcomes in this vulnerable population.
ICU
$0.3135+Infinity%1D
Analyst Views on ICU
Wall Street analysts forecast ICU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ICU stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICU is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.310
Low
1.00
Averages
1.00
High
1.00
Current: 0.310
Low
1.00
Averages
1.00
High
1.00
No data
About ICU
SeaStar Medical Holding Corporation is a commercial-stage medical technology company, which is focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. The Company’s Selective Cytopheretic Device (SCD) is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. It has broad potential applications for patients suffering from both acute and chronic kidney disease as well as cardiovascular and other serious inflammatory diseases. Its SCD therapy is an extracorporeal synthetic membrane device designed to bind activated leukocytes (neutrophils and monocytes) when integrated into an existing continuous renal replacement therapy (CRRT) circuit in conjunction with the use of regional citrate anticoagulation (RCA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
